Viking Therapeutics enjoyed a nice share rally on the news that rival Pfizer is discontinuing obesity candidate danuglipron.

Once-weekly basal insulin combined with an intermittently scanned continuous glucose monitor reduced HbA1c and improved time ...

Gireesh Babu, New Delhi Monday, April 14, 2025, 08:00 Hrs [IST] ...

Growth Driven by Advancements in Diagnostic Technologies and Rising Cancer Incidences Cancer pain remains one of the most challenging and prevalent issues for patients undergoing cancer treatment.